Centessa Pharmaceuticals (STU:260) Ending Cash Position : €108.76 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals Ending Cash Position?

Centessa Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2024 was €108.76 Mil.

Centessa Pharmaceuticals's quarterly Ending Cash Position declined from Sep. 2023 (€160.69 Mil) to Dec. 2023 (€117.40 Mil) and declined from Dec. 2023 (€117.40 Mil) to Mar. 2024 (€108.76 Mil).

Centessa Pharmaceuticals's annual Ending Cash Position increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€371.60 Mil) but then declined from Dec. 2022 (€371.60 Mil) to Dec. 2023 (€117.40 Mil).

Centessa Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for Centessa Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals Ending Cash Position Chart

Centessa Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

14.91

5.94

371.60

117.40

Centessa Pharmaceuticals Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial										242.83	134.04	160.69	117.40	108.76

Centessa Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Centessa Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	360.973	+	-243.569
	=	117.40

Centessa Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	117.788	+	-9.027
	=	108.76

Centessa Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Centessa Pharmaceuticals (STU:260) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (STU:260) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

CNTA:USA

Address

1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT

Website

https://www.centessa.com

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Centessa Pharmaceuticals (STU:260) Headlines

No Headlines